Circulating Tumor Cells (CTC) for Colorectal Cancer by CellSearch, Blood
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
According to the American Cancer Society, colorectal cancer claims approximately 50,000 lives each year, the vast majority of which are a result of metastatic disease. Although there are many options for the treatment of metastatic colorectal cancer, oncologists often have to wait several months before they can determine if a specific treatment is beneficial to the patient.
The CellSearch System identifies and enumerates the number of circulating tumor cells (CTCs) in a blood specimen.(1) Studies suggest that the number of CTCs is associated with progression-free and overall survival in patients with metastatic colorectal cancer.(2,3)
An aid in the monitoring of patients with metastatic colon cancer
In patients with metastatic colon cancer, the finding of > or =3 circulating tumor cells/7.5 mL of blood is predictive of shorter progression-free survival and overall survival.(2)
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This test is only for monitoring colon cancer patients with metastatic disease; it is not cleared by the FDA for colon cancer patients without metastatic disease.
Patients on doxorubicin (Adriamvcin) must wait a minimum of 7 days after administration before blood can be drawn for this test.
Blood specimens must be drawn into a CellSave tube and be processed in the laboratory within 96 hours of draw.
This test does not provide information about the primary site of a tumor.
This test does not predict whether patients with unfavorable results will have better clinical outcomes if switched to alternative treatment regimens.
The CellSearch System has also been FDA cleared for breast and prostate cancer. For breast cancer, order CTCB / Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch, Blood.
The presence of ferrofluid aggregates observed after processing a patient specimen may lead to false negative results. A result from a specimen in which aggregation is observed and the CTC count is below 3 is invalid and the test is canceled per manufacturer's instructions. A retest is advised.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
An interpretive report will be provided.
Clinical References Provides recommendations for further in-depth reading of a clinical nature
1. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004 Oct;10:6897-6904
2. Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008 Jul;26(19):3213-3221
3. Cohen SJ, Punt CJ, Iannotti N, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009;20(7):1223-1229
4. Package insert: CellSearch Circulating Tumor Cell (CTC) Kit. Veridex, LLC, Raritan, NJ